A randomized phase II trial of osimertinib, a representative EGFR-tyrosine kinase inhibitor, with or without LAT for patients harboring EGFR mutations with oligo-metastatic NSCLC is currently ongoing [26]. This evidence concerns the gene LAT and non-small cell lung carcinoma.